About this trial
Wide variability in the antiplatelet effects of aspirin may lead to recurrent thromboembolic events. Several pilot studies have suggested potential benefits of taking aspirin at bedtime rather than in the morning. The primary objective of this study is to examine whether aspirin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking aspirin.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age >=18 years
Current chronic treatment with aspirin (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire)
Signed informed consent
Disqualifiers
There are no exclusion criteria for this trial
Trial design
Parallel
Treatments tested in this trial
Aspirin
DrugAspirin at currently prescribed dose
Treatment groups
Trial outcomes
Primary outcomes
Composite of hospitalization for myocardial infarction, hospitalization for stroke, coronary revascularization, or cardiovascular death
Secondary outcomes
Hospitalization for myocardial infarction
Hospitalization for stroke
Coronary revascularization
Cardiovascular death
Other outcomes
Bleeding episode requiring hospitalization
Hospitalization for intracranial hemorrhage
Hospitalization for gastrointestinal hemorrhage
Hospitalization for unstable angina
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Tor Biering-Sørensen
Lead sponsor
Herlev and Gentofte Hospital
Sponsor institution